News
Eli Lilly obesity pill disappoints and gives boost to arch-rival Novo Nordisk
Shares in US-based Lilly fell 14.2 per cent on the trial results, while stock in Danish arch-rival Novo Nordisk, the maker of the pioneering Ozempic weight-loss drug, rose 6.7 per cent. Novo Nordisk has been losing share to Lilly in the US in injectable weight-loss drugs.
Danish drugmakers jump as Eli Lilly's weight-loss pill data disappoints
Shares in Novo Nordisk rose as much as 14% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell short of expectations, boosting investor confidence in the Danish drugmaker's market-leading obesity treatment.
The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...
The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...
Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...
Futurism on MSN20h
The Creator of Ozempic Is in Terrible TroubleNovo Nordisk's flagship product is semaglutide. Sold under the names Ozempic and Wegovy, it's one of the leading GLP-1 ...
Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of ...
The public is advised to check their drug's batch number, as those in possession of Ozempic from batch number PP5N682::RN287 ...
Novo Nordisk hit by slowing Ozempic sales, Tesla shareholders sue Musk over Robotaxi - Stock market news and latest business ...
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...
Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...
Some studies have linked the popular weight-loss drugs with a potentially higher risk of eye problems and vision loss. Should ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback